Prestige Consumer Healthcare Inc. (PBH) 10-Year Financial Performance & Capital Metrics

PBH • • Industrial / General

HealthcareMedical DistributionConsumer Healthcare ProductsOTC Healthcare Brands

AboutPrestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.Show more

Revenue $1.14B +1.1%
EBITDA $367M -1.6%
Net Income $215M +2.5%
EPS (Diluted) 4.29 +2.9%
Gross Margin 55.76% +0.5%
EBITDA Margin 32.25% -2.7%
Operating Margin 29.6% -2.7%
Net Margin 18.86% +1.4%
ROE 12.3% -8.9%
ROIC 9.14% -2.1%
Debt/Equity 0.57 -17.4%
Interest Coverage 7.07 +38.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 8/9
✓FCF machine: 21.4% free cash flow margin
✓Healthy 5Y average net margin of 13.3%

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y4.76%

5Y3.39%

3Y1.54%

TTM0.03%

Profit (Net Income) CAGR

10Y10.61%

5Y8.57%

3Y1.48%

TTM-2.48%

EPS CAGR

10Y11.15%

5Y9.06%

3Y2.02%

TTM-1.95%

ROCE

10Y Avg7.13%

5Y Avg7.8%

3Y Avg6.8%

Latest10.37%

Peer Comparison

OTC Healthcare Brands

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
PBHPrestige Consumer Healthcare Inc.	3.15B	65.61	15.29	1.1%	18.08%	11%	7.71%	0.57
SNYRSynergy CHC Corp.	20.48M	1.82	6.50	-18.57%	7.46%

Profit & Loss

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales/Revenue+	806.25M	882.06M	1.04B	975.78M	963.01M	943.37M	1.09B	1.13B	1.13B	1.14B
Revenue Growth %	0.13%	0.09%	0.18%	-0.06%	-0.01%	-0.02%	0.15%	0.04%	-0%	0.01%
Cost of Goods Sold+	339.04M	381.77M	464.67M	420.2M	410.79M	395.89M	466.17M	502.43M	500.91M	503.3M
COGS % of Revenue	0.42%	0.43%	0.45%	0.43%	0.43%	0.42%	0.43%	0.45%	0.45%	0.44%
Gross Profit+	467.21M	500.29M	576.5M	555.58M	552.22M	547.47M	620.65M	625.29M	624.45M	634.46M
Gross Margin %	0.58%	0.57%	0.55%	0.57%	0.57%	0.58%	0.57%	0.55%	0.55%	0.56%
Gross Profit Growth %	0.15%	0.07%	0.15%	-0.04%	-0.01%	-0.01%	0.13%	0.01%	-0%	0.02%
Operating Expenses+	206.9M	242.85M	360.64M	259.9M	261.07M	250.07M	290.73M	647.71M	282.02M	297.69M
OpEx % of Revenue	0.26%	0.28%	0.35%	0.27%	0.27%	0.27%	0.27%	0.57%	0.25%	0.26%
Selling, General & Admin	183.22M	217.5M	332.21M	232.85M	236.31M	223.69M	264.8M	252.41M	259.47M	263.93M
SG&A % of Revenue	0.23%	0.25%	0.32%	0.24%	0.25%	0.24%	0.24%	0.22%	0.23%	0.23%
Research & Development	0	0	0	0	0	0	0	0	0	0
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	23.68M	25.35M	28.43M	-476K	24.76M	26.38M	25.93M	395.29M	22.55M	33.76M
Operating Income+	260.31M	205.61M	215.87M	67.5M	291.15M	297.4M	329.92M	-22.41M	342.43M	336.77M
Operating Margin %	0.32%	0.23%	0.21%	0.07%	0.3%	0.32%	0.3%	-0.02%	0.3%	0.3%
Operating Income Growth %	0.25%	-0.21%	0.05%	-0.69%	3.31%	0.02%	0.11%	-1.07%	16.28%	-0.02%
EBITDA+	283.99M	231.41M	249.29M	99.28M	328.94M	327.57M	362.01M	10.21M	373.1M	366.95M
EBITDA Margin %	0.35%	0.26%	0.24%	0.1%	0.34%	0.35%	0.33%	0.01%	0.33%	0.32%
EBITDA Growth %	0.26%	-0.19%	0.08%	-0.6%	2.31%	-0%	0.11%	-0.97%	35.54%	-0.02%
D&A (Non-Cash Add-back)	23.68M	25.79M	33.43M	31.78M	37.78M	30.16M	32.09M	32.63M	30.68M	30.17M
EBIT	242.51M	204.4M	322.3M	67.03M	287.72M	286.44M	326.75M	-24.75M	343.19M	331.82M
Net Interest Income+	-85.16M	-93.34M	-105.88M	-105.08M	-96.22M	-82.33M	-64.29M	-69.16M	-67.16M	-47.63M
Interest Income	162K	203K	388K	217K	342K	0	0	0	0	0
Interest Expense	85.32M	93.55M	106.27M	105.3M	96.57M	82.33M	64.29M	69.16M	67.16M	47.63M
Other Income/Expense	-103.13M	-94.79M	-108.39M	-105.56M	-100M	-93.29M	-67.46M	-71.5M	-66.4M	-52.59M
Pretax Income+	157.19M	110.85M	107.09M	-38.05M	191.15M	204.11M	262.46M	-93.92M	276.02M	284.19M
Pretax Margin %	0.19%	0.13%	0.1%	-0.04%	0.2%	0.22%	0.24%	-0.08%	0.25%	0.25%
Income Tax+	57.28M	41.45M	-232.48M	-2.25M	48.87M	39.43M	57.08M	-11.61M	66.69M	69.58M
Effective Tax Rate %	0.64%	0.63%	3.17%	0.94%	0.74%	0.81%	0.78%	0.88%	0.76%	0.76%
Net Income+	99.91M	69.39M	339.57M	-35.8M	142.28M	164.68M	205.38M	-82.31M	209.34M	214.6M
Net Margin %	0.12%	0.08%	0.33%	-0.04%	0.15%	0.17%	0.19%	-0.07%	0.19%	0.19%
Net Income Growth %	0.28%	-0.31%	3.89%	-1.11%	4.97%	0.16%	0.25%	-1.4%	3.54%	0.03%
Net Income (Continuing)	99.91M	69.39M	339.57M	-35.8M	142.28M	164.68M	205.38M	-82.31M	209.34M	214.6M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	1.88	1.30	6.34	-0.69	2.78	3.25	4.04	-1.65	4.17	4.29
EPS Growth %	0.26%	-0.31%	3.88%	-1.11%	5.03%	0.17%	0.24%	-1.41%	3.53%	0.03%
EPS (Basic)	1.89	1.31	6.34	-0.69	2.81	3.28	4.09	-1.65	4.21	4.32
Diluted Shares Outstanding	53.14M	53.36M	53.53M	52.07M	51.14M	50.6M	50.84M	49.89M	50.18M	50.08M
Basic Shares Outstanding	52.75M	52.98M	53.1M	51.88M	50.72M	50.21M	50.26M	49.88M	49.76M	49.7M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Current Assets+	249.01M	334.43M	303.48M	300.94M	365.65M	269.83M	293.27M	391.74M	375.04M	448.33M
Cash & Short-Term Investments	27.23M	41.85M	32.55M	27.53M	94.76M	32.3M	27.18M	58.49M	46.47M	97.88M
Cash Only	27.23M	41.85M	32.55M	27.53M	94.76M	32.3M	27.18M	58.49M	46.47M	97.88M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	95.25M	136.74M	140.88M	148.79M	150.52M	114.67M	139.33M	167.02M	176.78M	194.29M
Days Sales Outstanding	43.12	56.58	49.39	55.66	57.05	44.37	46.79	54.06	57.34	62.33
Inventory	91.26M	115.61M	118.55M	119.88M	116.03M	114.96M	120.34M	162.12M	138.72M	147.71M
Days Inventory Outstanding	98.25	110.53	93.12	104.13	103.09	105.99	94.23	117.78	101.08	107.12
Other Current Assets	10.11M	40.23M	0	4.74M	0	0	0	4.12M	13.08M	8.44M
Total Non-Current Assets+	2.7B	3.58B	3.46B	3.14B	3.15B	3.16B	3.38B	2.96B	2.94B	2.95B
Property, Plant & Equipment	15.54M	50.59M	52.55M	51.18M	90.72M	102.77M	98.53M	89.53M	89.33M	127.84M
Fixed Asset Turnover	51.88x	17.43x	19.81x	19.07x	10.62x	9.18x	11.03x	12.60x	12.60x	8.90x
Goodwill	360.19M	615.25M	620.1M	578.58M	575.18M	578.08M	578.98M	527.55M	527.73M	527.42M
Intangible Assets	2.32B	2.9B	2.78B	2.51B	2.48B	2.48B	2.7B	2.34B	2.32B	2.3B
Long-Term Investments	-10.11M	-715.09M	-26K	-399.57M	0	0	0	0	0	0
Other Non-Current Assets	1.32M	7.45M	3.57M	3.13M	2.96M	2.86M	3.27M	3M	5.72M	3.27M
Total Assets+	2.95B	3.91B	3.76B	3.44B	3.51B	3.43B	3.67B	3.35B	3.32B	3.4B
Asset Turnover	0.27x	0.23x	0.28x	0.28x	0.27x	0.28x	0.30x	0.34x	0.34x	0.33x
Asset Growth %	0.1%	0.33%	-0.04%	-0.08%	0.02%	-0.02%	0.07%	-0.09%	-0.01%	0.03%
Total Current Liabilities+	106.68M	162.01M	123.2M	126.98M	149.88M	122.14M	143.42M	160.72M	117.05M	106.62M
Accounts Payable	38.3M	70.22M	61.39M	56.56M	62.38M	45.98M	55.76M	62.74M	38.98M	18.93M
Days Payables Outstanding	41.23	67.13	48.22	49.13	55.42	42.39	43.66	45.58	28.4	13.72
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	492K	0	0	0	0	0	0	0	0
Other Current Liabilities	11.31M	22.84M	1.9M	88K	13.39M	14.07M	19.59M	14.29M	57.13M	14.21M
Current Ratio	2.33x	2.06x	2.46x	2.37x	2.44x	2.21x	2.04x	2.44x	3.20x	4.20x
Quick Ratio	1.48x	1.35x	1.50x	1.43x	1.67x	1.27x	1.21x	1.43x	2.02x	2.82x
Cash Conversion Cycle	100.14	99.98	94.28	110.66	104.72	107.97	97.36	126.25	130.01	155.73
Total Non-Current Liabilities+	2.1B	2.93B	2.46B	2.22B	2.19B	1.95B	1.95B	1.75B	1.55B	1.46B
Long-Term Debt	1.63B	2.19B	1.99B	1.8B	1.73B	1.48B	1.48B	1.35B	1.13B	992.36M
Capital Lease Obligations	0	0	0	0	29.5M	26.52M	20.59M	11.54M	7.7M	43.36M
Deferred Tax Liabilities	469.62M	715.09M	442.52M	399.57M	407.81M	434.05M	444.92M	380.43M	403.6M	419.59M
Other Non-Current Liabilities	2.84M	17.97M	23.33M	20.05M	25.44M	8.61M	7.48M	8.16M	9.19M	5.39M
Total Liabilities	2.2B	3.09B	2.58B	2.35B	2.34B	2.07B	2.09B	1.91B	1.66B	1.57B
Total Debt+	1.63B	2.19B	1.99B	1.8B	1.77B	1.51B	1.51B	1.37B	1.14B	1.04B
Net Debt	1.6B	2.15B	1.96B	1.77B	1.67B	1.48B	1.48B	1.31B	1.09B	946.37M
Debt / Equity	2.18x	2.67x	1.69x	1.64x	1.51x	1.12x	0.95x	0.94x	0.69x	0.57x
Debt / EBITDA	5.72x	9.48x	7.99x	18.12x	5.37x	4.62x	4.16x	133.90x	3.05x	2.85x
Net Debt / EBITDA	5.63x	9.30x	7.86x	17.84x	5.08x	4.53x	4.09x	128.17x	2.93x	2.58x
Interest Coverage	3.05x	2.20x	2.03x	0.64x	3.02x	3.61x	5.13x	-0.32x	5.10x	7.07x
Total Equity+	744.34M	822.55M	1.18B	1.1B	1.17B	1.36B	1.58B	1.45B	1.66B	1.83B
Equity Growth %	0.19%	0.11%	0.43%	-0.07%	0.07%	0.16%	0.16%	-0.08%	0.14%	0.11%
Book Value per Share	14.01	15.41	22.02	21.05	22.90	26.84	31.03	29.01	32.98	36.64
Total Shareholders' Equity	744.34M	822.55M	1.18B	1.1B	1.17B	1.36B	1.58B	1.45B	1.66B	1.83B
Common Stock	530K	533K	534K	536K	538K	540K	544K	548K	555K	560K
Retained Earnings	327.31M	396.71M	736.28M	701.82M	844.1M	1.01B	1.21B	1.13B	1.34B	1.56B
Treasury Stock	-5.16M	-6.59M	-7.67M	-59.93M	-117.62M	-130.73M	-133.65M	-189.11M	-219.62M	-277.21M
Accumulated OCI	-23.52M	-26.35M	-19.32M	-25.75M	-44.16M	-19.8M	-19.03M	-31.56M	-34.49M	-37.66M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations+	174.35M	147.77M	210.11M	189.28M	217.12M	235.61M	259.92M	229.72M	248.93M	251.51M
Operating CF Margin %	0.22%	0.17%	0.2%	0.19%	0.23%	0.25%	0.24%	0.2%	0.22%	0.22%
Operating CF Growth %	0.12%	-0.15%	0.42%	-0.1%	0.15%	0.09%	0.1%	-0.12%	0.08%	0.01%
Net Income	99.91M	69.39M	339.57M	-35.8M	142.28M	164.68M	205.38M	-82.31M	209.34M	214.6M
Depreciation & Amortization	23.68M	25.79M	33.43M	31.78M	29M	30.16M	32.09M	32.63M	30.68M	30.17M
Stock-Based Compensation	9.95M	8.15M	8.91M	7.44M	7.64M	8.54M	9.04M	12.4M	14.01M	11.16M
Deferred Taxes	46.15M	-5.78M	-269.09M	-40.55M	13.85M	18.63M	9.98M	-60.77M	23.07M	0
Other Non-Cash Items	16.44M	63.55M	113.05M	234.74M	15.55M	19.19M	14.38M	381.61M	11.66M	37.52M
Working Capital Changes	-21.78M	-13.34M	-15.76M	-8.32M	8.8M	-5.6M	-10.95M	-53.85M	-39.83M	-41.94M
Change in Receivables	1.82M	-18.94M	-5.04M	-2.98M	-2.85M	36.87M	-24.65M	-24.93M	-6.32M	-16.33M
Change in Inventory	-3M	-10.26M	-2.48M	-10.54M	2.93M	2.97M	663K	-42.23M	24.44M	-9.31M
Change in Payables	-11.35M	21.45M	-10.03M	-3.99M	6.21M	-17.34M	9.15M	7.26M	-24.97M	-19.41M
Cash from Investing+	-222.97M	-694.6M	-11.56M	55.43M	-16.57M	-22.24M	-256.51M	-11.58M	-20.11M	-17.45M
Capital Expenditures	-3.57M	-2.98M	-12.53M	-10.48M	-14.56M	-22.24M	-9.64M	-7.78M	-9.55M	-8.22M
CapEx % of Revenue	0%	0%	0.01%	0.01%	0.02%	0.02%	0.01%	0.01%	0.01%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	7.58M	1.5M	970K	65.91M	750K	0	0	0	0	0
Cash from Financing+	54.04M	561.86M	-208.96M	-249.33M	-131.43M	-279.42M	-7.57M	-185.85M	-241.01M	-182.07M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-12.1M	-6.21M	45K	-2.28M	-6.23M	-16.11M	-1.99M	1.91M	11.81M	-5.83M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	170.78M	144.79M	197.58M	178.8M	202.56M	213.36M	250.28M	221.93M	239.38M	243.29M
FCF Margin %	0.21%	0.16%	0.19%	0.18%	0.21%	0.23%	0.23%	0.2%	0.21%	0.21%
FCF Growth %	0.14%	-0.15%	0.36%	-0.1%	0.13%	0.05%	0.17%	-0.11%	0.08%	0.02%
FCF per Share	3.21	2.71	3.69	3.43	3.96	4.22	4.92	4.45	4.77	4.86
FCF Conversion (FCF/Net Income)	1.75x	2.13x	0.62x	-5.29x	1.53x	1.43x	1.27x	-2.79x	1.19x	1.17x
Interest Paid	79.13M	85.21M	98.57M	98.23M	92.17M	80.29M	61.36M	54.24M	63.25M	47.8M
Taxes Paid	15.35M	48M	24.44M	32.8M	30.6M	34.38M	46.57M	40.74M	59.64M	52.12M

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	14.56%	8.86%	33.94%	-3.15%	12.55%	13.02%	13.99%	-5.44%	13.5%	12.3%
Return on Invested Capital (ROIC)	8.61%	5.8%	5.3%	1.69%	7.65%	7.85%	8.39%	-0.58%	9.33%	9.14%
Gross Margin	57.95%	56.72%	55.37%	56.94%	57.34%	58.03%	57.11%	55.45%	55.49%	55.76%
Net Margin	12.39%	7.87%	32.61%	-3.67%	14.77%	17.46%	18.9%	-7.3%	18.6%	18.86%
Debt / Equity	2.18x	2.67x	1.69x	1.64x	1.51x	1.12x	0.95x	0.94x	0.69x	0.57x
Interest Coverage	3.05x	2.20x	2.03x	0.64x	3.02x	3.61x	5.13x	-0.32x	5.10x	7.07x
FCF Conversion	1.75x	2.13x	0.62x	-5.29x	1.53x	1.43x	1.27x	-2.79x	1.19x	1.17x
Revenue Growth	12.82%	9.4%	18.04%	-6.28%	-1.31%	-2.04%	15.21%	3.76%	-0.21%	1.1%

Revenue by Segment

	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Gastrointestinal	94.59M	101.31M	152.24M	160.46M	172.91M	161.14M	204.56M	226.58M	231.61M	255.94M
Gastrointestinal Growth	-	7.11%	50.26%	5.40%	7.76%	-6.81%	26.95%	10.77%	2.22%	10.51%
Women's Health	135.17M	150.88M	259.38M	258.48M	251.55M	268.1M	264.51M	251.35M	240.42M	236.83M
Women's Health Growth	-	11.63%	71.91%	-0.35%	-2.68%	6.58%	-1.34%	-4.97%	-4.35%	-1.49%
Eye and Ear Care	107.5M	109.69M	104.05M	112.84M	112.16M	110.41M	163.45M	171.08M	179.42M	183.32M
Eye and Ear Care Growth	-	2.04%	-5.14%	8.44%	-0.60%	-1.56%	48.04%	4.67%	4.88%	2.17%
Dermatologicals	85.07M	87.35M	96.89M	97.97M	103.01M	107.08M	120.39M	123.74M	129.1M	128.95M
Dermatologicals Growth	-	2.68%	10.92%	1.12%	5.14%	3.95%	12.42%	2.79%	4.33%	-0.12%
Analgesics	119.47M	122.17M	119.42M	114.18M	114.01M	119.14M	119.32M	119.26M	117.45M	117.7M
Analgesics Growth	-	2.27%	-2.26%	-4.39%	-0.15%	4.50%	0.15%	-0.05%	-1.52%	0.21%
Cough and Cold	116.57M	108.78M	111.85M	103.12M	111.11M	70.64M	107.08M	126.99M	119.02M	106.21M
Cough and Cold Growth	-	-6.68%	2.81%	-7.80%	7.74%	-36.42%	51.58%	18.59%	-6.27%	-10.76%
Oral Care	51.13M	108.1M	111M	103.43M	93.2M	101.43M	97.52M	97.63M	96.31M	95.03M
Oral Care Growth	-	111.44%	2.69%	-6.82%	-9.89%	8.83%	-3.85%	0.11%	-1.35%	-1.32%
Other OTC	6.1M	5.83M	5.71M	5.48M	5.07M	5.43M	9.98M	11.1M	12.03M	13.78M
Other OTC Growth	-	-4.43%	-2.11%	-3.91%	-7.62%	7.13%	84.02%	11.14%	8.36%	14.58%
Household Cleaning	90.66M	87.93M	80.65M	19.81M	-	-	-	-	-	-
Household Cleaning Growth	-	-3.01%	-8.28%	-75.43%	-	-	-	-	-	-

Revenue by Geography

	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
UNITED STATES	-	-	-	837.05M	812.65M	799.04M	910.11M	953.22M	886.47M	897.54M
UNITED STATES Growth	-	-	-	-	-2.91%	-1.68%	13.90%	4.74%	-7.00%	1.25%
Non-US	-	-	-	138.73M	150.36M	144.33M	176.71M	174.5M	238.89M	240.22M
Non-US Growth	-	-	-	-	8.38%	-4.01%	22.43%	-1.25%	36.90%	0.56%

Frequently Asked Questions

Valuation & Price

Prestige Consumer Healthcare Inc. (PBH) has a price-to-earnings (P/E) ratio of 15.3x. This is roughly in line with market averages.

Growth & Financials

Prestige Consumer Healthcare Inc. (PBH) reported $1.11B in revenue for fiscal year 2025. This represents a 152% increase from $441.1M in 2012.

Prestige Consumer Healthcare Inc. (PBH) grew revenue by 1.1% over the past year. Growth has been modest.

Yes, Prestige Consumer Healthcare Inc. (PBH) is profitable, generating $200.8M in net income for fiscal year 2025 (18.9% net margin).

Dividend & Returns

Prestige Consumer Healthcare Inc. (PBH) has a return on equity (ROE) of 12.3%. This is reasonable for most industries.

Prestige Consumer Healthcare Inc. (PBH) generated $255.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...